Based on preclinical testing, mtor inhibitors were predicted to be effective in the treatment of tumours with genetic mutations that lead to overactivation of mtor signalling—for example, loss of pten, Stk11 (Lkb1), or Tsc2. The gene discussed is STK11; the disease is neoplasm.